





IAKII 107	A JOHAT FA	NN HISTOI	XI
Is it really the joint?	Acute vs Chronic	Age of onset	Number of joints involve
Symmetry? Additive or migratory?	Nature of pain: aching, sharp, burning, stiff, etc	Joint swelling	Aggravating: Time of day, activity/rest
	Relieving: Medications, activity/rest	History of joint injuries or procedures	





Monoarticular (I Joint) - Sepic arthritis - Cox - Prendopout (CPTO) - Post-traumatic orrecoarthritis Polyarticular (5 or more joints) - RA - RA - RA - SLE/CTD - Virial (HBV, HCV, Parvo, Covid 19, etc.) - Oxtecarthritis Polyarticular (5 or more joints) - Summary statement - Number of joints involved - Symmetric or not - Symmetric

10

CASE #1 CONTINUED


Our patient reports the only pain she previously had was lower back pain but starting about 5 months ago she began having pain in her hands and feet. Pain is worse first thing in the morning, joints feel stiff for 90 minutes and gradually improve as the day progresses. She is not sure if she has had any joint swelling. When you ask her to point to the area that hurts the most she points to...

11

PATIENT'S HAND Joints feel boggy, slightly warm and tender. Cannot appreciate distinct; joint line. Patient cannot make a tight fist or claw.



EPIDEMIOLOGY OF OAVS RA RHEUMATOID ARTHRITIS Prevalence: 0.5-1% Increases with age Typical age of onset 40-60 for females. a bit older for males Peak incidence ages 50-60 Females 2-3 x greater than males 1.7x for knee OA Typical ages 50-80 Female > male 1.7x for knee OA





X-rays of affected joints Particularly if symptoms for > 1 year Hand and foor x-rays are more helpful in evaluation of inflammatory arthritis as these can show pertirectual resteogenia and erosions Lower-extremty joints should be radiographed while weightbearing if possible Laboratory evaluation Sedimentation rats. C-reactive protein, Rheumstool factor, anti-cirullinated peptide anthodes (ACPA or CCP), IVCVA, HBA/g I would add ANA if there are mucocutineous manifestations or significant systemic symptoms I would add and and for mono or oligoarticular arthrisis, particularly of the lower extremities and if the patient is male or has CKD Symovial fluid analysis for crystals, cell count and diff, and culture can be helpful for mono or oligoarticular arthrisis



RHEUMATOID FACTOR Sensitivity: 69% · IgM autoantibody directed against Fc portion of IgG • Specificity:85% Found in 5% of healthy individuals, increasing to up Positive likelihood ratio: 4.9 Negative likelihood ratio: 0.38 to 15% with age · Association with other Association with other diseases: Sjogren's (up to 50%), Lupus (15-20%), Chronic HCV (~50%), bacterial endocarditis (40%), sarcoidosis, parvovirus, etc https://www.ksvdl.org/images/diagnositc_insight s/mar2019/Figure-1.jpg

19

ANTI-CITRULLINATED PEPTIDE ANTIBODIES

- Referred to as ACPA or CCP
- Should be measured when you are sending RF
- Sensitivity: 67% Specificity: 95%
- High titers (>3x ULN) signify worse prognosis but are not useful as markers of disease activity

20

CASE #1 CONCLUSION

- Labs show RF 60 (positive), ESR 45 (elevated), CRP 1.7 mg/dL (elevated) and CCP negative. Hand and foot x-rays are normal.
- Next steps:


 - Refer to rheumatology
 Trial of NSAIDs in appropriate patients Consider prednisone


 - Do not use doses of prednisone >20mg daily for RA
 It is better to avoid it if possible

 - n. a. vetter to aroot it is postible

 Start at 15-30g and taper over 2-3 weeks to 5-7-5ng daily or every other day.
 Can prescribe as 5-10ng daily as needed for joint paintwelling.
 A steroid pack or IM injection can be useful to determine steroid responsiveness but not as ongoing treatment (this is a chronic inflammatory arthritis).

* 35-year-old female with a history of hypothyroidism, depression, eczema who is complaining of fatigue and joint pain. You are covering for her primary care doctor who had checked labs and found a positive antinuclear antibody (ANA) titer 1:80. What is your approach?





ANA titer	N	N with rheumatic disease
1:40	27	0
1:80	28	0
1:160	71	I (Lupus)
1:320	34	I (Sjogren's)
1:640	31	4 (2 lupus, 2 Sjogren's)
1:1280	23	8 (2 lupus, 4 Sjogren's, 1 systemic sclerosis, I undifferentiated connective tissue disease)
1:2560	6	2 (1 systemic sclerosis, 1 Sjogren's)
1:5120	5	I (undifferentiated connective tissue disease)
Total	232	17
	tive value c	not associated with rheumatologic conditions of + ANA 2.1% for SLE, 9.1% for any
111111	#11	(Am Med 201


Many non-rheumatologic conditions are associated with a positive ANA (chronically or transiently) Infections (viral especially), malignancies (solid and hematologic), autoimmune thyroid disease, multiple sclerosis, monoclonal antibody therapies, vaccinations Detectable ANA titers are present in up to 25% of the population Changes in ANA titers are not a marker of disease activity or severity Positive ANA does not confirm any diagnosis Titers should generally not be repeated unless there is a change in symptoms or concern for transient ANA elevation It is not appropriate to order ANAs as screening for patients with family history of autoimmune disease in the absence of symptoms Axial/spinal pain is not an indication for ANA testing


26


IFYOU HAVE HIGH CLINICAL SUSPICION FOR LUPUS AND + ANA, **FURTHER TESTING TO CONSIDER IS:** CBC with differential ENA panel • Creatinine • dsDNA Ab UA with microscopy • DAT (Coombs) Spot Urine Protein to • RF Creatinine Ratio • CCP C3 and C4 complements HBV and HCV Abs • HIV


ANII	GENS		
Autoantibody	Primary Disease	Sensitivity	Specificity
DsDNA Ab	SLE	30-80%	High
Smith Ab (Sm)	SLE	15-40%	High
Anti-RNP	SLE	15-40%	Low
	MCTD	100%	Low
Anti-Ro (SSA)	SLE	40%	Low
	SjS	20-75%	Low
ScI-70	SSc	25%	High
Anti-Centromere	Raynaud's	30%	Moderate
	SSc (limited, CREST)	50-90%	
	SSc (Diffuse)	25%	












ORAL ULCERS (MUCOSITIS) IN SLE Nasal and oral ulcerations Typically painless, asymmetric May flare with sun exposure Hard palate, buccal mucosa, vermillion border DDx: aphthous stomatitis,

GPA, celiac disease, Crohn's disease, HSV, Syphilis, viral infections

34



35



Try and differentiate between joint centered and non-joint pain Try and differentiate between inflammatory and non-inflammatory joint pain Try and develop a summary statement when evaluating a new patient with joint pain Have a high clinical suspicion (pre-test probability) before sending rheumatologic testing A negative ANA virtually excludes lupus Lab testing alone is not sufficient to diagnose systemic rheumatologic disease

37

Thank you to Dr. Jenna McGoldrick, Dr Sarah Ringsted, Dr. Nick Steinstra and Dr. Michael Davey for their work in making this presentation over the years.

38



DEFENENCES	
REFERENCES	
 Aringer, Martin, et al. "2019 European League Against Rheumatism/American College of Rheumatiology Classification Criteria for Systemic Lupus Erythematous." Arthritis & Rheumatology, no. 9, Wiley, Aug. 2015, pp. 1400–12. Coursef, doi:10.1002/art.40930. 	
 Fraenkel, Liana, et al. "2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis." Arthritis Care & Samp; Research, no. 7, Wiley, June 2021, pp. 924–39. Crossref, doi:10.1002/arc.24596. 	
 Stone, John. Current Diagnosis & Treatment in Rheumatology. Fourth Edition, McGraw-Hill Education / Medical, 2021. 	
 Stone, John. Current Diagnosis & Treatment in Rheumatology. Fourth Edition, McGraw-Hill Education / Medical, 2021. 	
 Toplak N., et al. "Autoimmune Response Following Annual Influenza Vaccination in 92 Apparently Healthy Adults." Autoimmunity Reviews. no. 2, Bsevier BV, Dec. 2008, pp. 134–38. Crossref, doi:10.1016/j.autrev.2008.07.008. 	
 Yes, All Lt. et al. "Utility of Repeated Antimiclear Antibody Tests: A Retrospective Database Study." The Lanced Manufaction, no. 7. Beviere BV, July 2020, pp. e412–17. Crosser, doi:10.1076/r2665-97.10(20)50064-9. 	